Exxonmobil Investment Management Inc. TX lowered its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 13.6% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 43,115 shares of the biopharmaceutical company’s stock after selling 6,764 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Alexion Pharmaceuticals were worth $5,246,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Guardian Life Insurance Co. of America boosted its position in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the last quarter. Grandfield & Dodd LLC boosted its position in shares of Alexion Pharmaceuticals by 1.5% in the first quarter. Grandfield & Dodd LLC now owns 3,270 shares of the biopharmaceutical company’s stock valued at $396,000 after buying an additional 47 shares during the last quarter. Cleararc Capital Inc. boosted its position in shares of Alexion Pharmaceuticals by 1.0% in the first quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock valued at $666,000 after buying an additional 53 shares during the last quarter. Bremer Trust National Association boosted its position in shares of Alexion Pharmaceuticals by 1.7% in the first quarter. Bremer Trust National Association now owns 5,484 shares of the biopharmaceutical company’s stock valued at $665,000 after buying an additional 94 shares during the last quarter. Finally, Rathbone Brothers plc boosted its position in shares of Alexion Pharmaceuticals by 5.3% in the first quarter. Rathbone Brothers plc now owns 1,990 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 100 shares during the last quarter. 94.37% of the stock is currently owned by institutional investors.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 136.64 on Monday. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $145.41. The company has a market capitalization of $30.50 billion, a price-to-earnings ratio of 59.25 and a beta of 1.41. The company’s 50 day moving average price is $125.22 and its 200-day moving average price is $122.56.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The company had revenue of $912 million for the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.13 earnings per share. On average, equities analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.55 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/07/exxonmobil-investment-management-inc-tx-has-5-25-million-stake-in-alexion-pharmaceuticals-inc-nasdaqalxn-updated-updated-updated.html.

Several brokerages recently issued reports on ALXN. Stifel Nicolaus reaffirmed a “buy” rating and set a $157.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. UBS AG reissued a “buy” rating and issued a $140.00 price objective (down previously from $143.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 31st. Jefferies Group LLC set a $120.00 price objective on Alexion Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, June 8th. Barclays PLC reissued an “overweight” rating and issued a $155.00 price objective on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 9th. Finally, J P Morgan Chase & Co reissued a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, June 14th. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $156.89.

In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker acquired 660,779 shares of the stock in a transaction dated Thursday, June 15th. The shares were acquired at an average cost of $117.33 per share, for a total transaction of $77,529,200.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ludwig Hantson acquired 10,000 shares of the stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average price of $116.72 per share, for a total transaction of $1,167,200.00. Following the completion of the transaction, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at $4,519,982. The disclosure for this purchase can be found here. Insiders bought 2,019,734 shares of company stock worth $235,606,846 over the last 90 days. Company insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.